The idea of the body count evolves https://t.co/AnYgP3VPTp ...

[Music] [Applause] Hi everyone, my name is Kate from mywanjo. In our whimsical words, we would like to believe there's equality between gender. Thus, we successfully overcame gender stereotypes.Thus, we fully acquire our body positivity. But you know that actually we are as far from that as we could be. And today I'm going to share my own experiences and observations about female stereotypes.I still remember that I posted WeChat moment when I was grade seven. It was 3 years ago and I will never forget it. I ...

Developing Breakthrough Biologics, Life-changing Medicines® Corporate Update June 10, 2025 Legal Notices The information in this slide deck is current as of June 10, 2025, unless otherwise noted, and is qualified in its entirety by reference to MacroGenics' Annual, Quarterly and Current Reports filed with the SEC. MacroGenics undertakes no obligation to update any of the information herein. Cautionary Note on Forward-Looking Statements Any statements in this presentation about future expectations, plans and ...

Pipeline Highlights - Varegacestat, an oral gamma secretase inhibitor for desmoid tumors, expects Phase 3 topline data in the second half of 2025[10] - IM-1021, a ROR1 ADC, is currently in a Phase 1 trial[10] - IM-3050, a FAP radiotherapy, anticipates Phase 1 initiation in the second half of 2025[10] - Three novel ADCs against solid tumor targets are undergoing IND-enabling studies[10] Varegacestat Clinical Data - Phase 2 RINGSIDE Part A data showed a 64% response rate in the 12mg QD arm (n=14) and 55% overall (n=42)[33] - Varegacestat demonstrated a 75% ORR by RECIST in the ITT population (n=14), compared to 41% for Nirogacestat (n=70)[32] - Varegacestat showed -88% median best tumor volume reduction in evaluable patients (n=12), compared to -59% for Nirogacestat (n=61)[32] IM-1021 Development - IM-1021 is in Phase 1 clinical trials, with the first patient dosed in 1Q25[50] - Preclinical data shows IM-1021 achieved 8/8 CR at 2.5 mg/kg in NSCLC PDX Model[58] ADC Discovery and Strategy - The company has screened ~1000 targets, evaluated 15+ targets in vivo, and has 3 novel solid tumor ADCs in IND-enabling studies[70] - Top 10 targets account for 55% of active clinical ADC programs[74]

Communication Skills Improvement Strategies - Observation and imitation are crucial for effective communication, focusing on body language, tonality, and voice modulation [1] - Active listening is key to becoming a fluent speaker, emphasizing careful attention to podcasts, speeches, and audiobooks [1] - Reading aloud helps practice speaking, allows self-feedback, and encourages passionate presentation [1] - Mastering pronunciation is essential for clarity, with specific examples provided to correct common mispronunciations [2] - Voice modulation and tonality, or feeling the words, are vital for conveying emotions and captivating the audience [5] - Pauses are a powerful tool for audience processing, thinking time, and eliminating filler words [8][9] - Body language accounts for 55% of communication effectiveness, emphasizing gestures, expressions, and confidence [14] Implementation and Review - The "R and R" (Record and Review) method is recommended for continuous improvement through video recording and self-assessment [17] - Visual review focuses on body language, while auditory review assesses tone, pauses, and filler words [17][18] Personal Development and Impact - Improving communication skills can lead to personal transformation and the ability to inspire others [1] - The speaker's mission is to empower individuals to become confident and visible through enhanced communication skills [20]

Global Leaders in IgM Antibodies JP Morgan Healthcare Conference January 12, 2022 Forward-looking statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that reflect the current views of IGM Biosciences, Inc. (the "Company," "we" or "our") with respect to the Company's future financial condition, results of operations, business strategy, expectations, milestones and plans. All statements other than statements of historica ...

Core Viewpoint - The FDA has granted accelerated approval for Lynozyfic™ (linvoseltamab-gcpt) to treat adult patients with relapsed or refractory multiple myeloma who have undergone at least four prior lines of therapy, marking a significant advancement in treatment options for this patient population [1][5][6]. Group 1: FDA Approval and Clinical Trial Results - Lynozyfic is the first FDA-approved BCMAxCD3 bispecific antibody, allowing for a flexible dosing schedule that can adapt based on patient response [2][3]. - The approval is based on the LINKER-MM1 trial, where 70% of patients achieved an overall response rate, with 45% achieving a complete response or better [6][5]. - The median time to first response was 0.95 months, and the median duration of response was not reached, with an estimated 89% of responders maintaining their response at 9 months [6][12]. Group 2: Safety and Administration - Lynozyfic has a Boxed Warning for cytokine release syndrome (CRS) and neurologic toxicity, with common adverse reactions including musculoskeletal pain, cough, and fatigue [4][18]. - The treatment involves a step-up dosing regimen, requiring hospitalization for safety during the initial doses [10][20]. - Lynozyfic is available only through a restricted program called the Lynozyfic Risk Evaluation and Mitigation Strategy (REMS) due to the associated risks [4][22]. Group 3: Company Commitment and Future Development - Regeneron is committed to advancing the treatment landscape for multiple myeloma and has launched Lynozyfic Surround™, providing financial and educational resources for patients [5][6]. - The company is rapidly advancing its clinical development program for Lynozyfic, exploring its use in earlier lines of therapy and in combination with other treatments [5][13]. - Regeneron utilizes its proprietary VelocImmune technology to develop Lynozyfic, showcasing its expertise in creating fully human antibodies [9][17].

Core Insights - Instil Bio, Inc. has received FDA clearance for the Investigational New Drug (IND) application for AXN-2510, a bispecific antibody targeting PD-L1 and VEGF, aimed at treating multiple solid tumors [1][3] - The company plans to initiate a phase 1 trial of AXN-2510 as a monotherapy for patients with relapsed/refractory solid tumors before the end of 2025 [2] - Initial safety and efficacy results from a phase 2 trial of AXN-2510 in combination with chemotherapy for first-line non-small cell lung cancer (NSCLC) in China are expected to be shared in the second half of 2025 [1][2] Company Overview - Instil Bio is a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies [3] - The lead asset, AXN-2510, is positioned as a differentiated treatment option for various solid tumors [3]

Review: On her fourth studio album, Lorde turns to glitchy, minimal electronic arrangements to explore various elements of her life, including body-image issues, insecurity and family dynamics https://t.co/rZ3sXc9CpW ...

Core Points - ADC Therapeutics SA has granted options to purchase 17,000 common shares to a new employee as an inducement for employment [1][2] - The grants were approved by the Compensation Committee under the Company's Inducement Plan to motivate and reward employees [2] - The options will vest 25% on the first anniversary of the grant date and 1/48th monthly thereafter, fully vesting by the fourth anniversary [3] Company Overview - ADC Therapeutics is a global leader in antibody drug conjugates (ADCs) and is focused on transforming treatment for hematologic malignancies and solid tumors [4] - The company's ADC ZYNLONTA has received accelerated approval from the FDA and conditional approval from the European Commission for treating relapsed or refractory diffuse large B-cell lymphoma [5] - ADC Therapeutics is headquartered in Lausanne, Switzerland, with operations in London and New Jersey [6]